Oxalo Therapeutics

Executive Summary

Oxalo Therapeutics is a preclinical-stage biopharmaceutical company pioneering first-in-class therapies for rare renal diseases driven by oxalate accumulation. Its lead program targets primary hyperoxaluria (PH), an ultra-rare genetic disorder that causes recurrent kidney stones and progressive renal failure due to excessive oxalate production. Inspired by oxalate-metabolizing enzymes from gut microbes, Oxalo's approach aims to degrade oxalate systemically, addressing the root cause rather than just symptoms. The company, founded in 2018 and based in Cambridge, MA, is privately held and has not disclosed funding rounds. With no approved therapies for PH that directly reduce oxalate production, Oxalo's platform holds transformative potential for patients, though it remains at an early development stage with significant technical and regulatory hurdles ahead. The success of its preclinical program and ability to secure financing will be critical to advancing toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND-enabling studies completion and regulatory filing55% success
• Q2 2026Series A financing round65% success
• Q3 2026Preclinical efficacy data presented at scientific conference80% success